DK0987256T3 - Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid - Google Patents

Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid

Info

Publication number
DK0987256T3
DK0987256T3 DK99117098T DK99117098T DK0987256T3 DK 0987256 T3 DK0987256 T3 DK 0987256T3 DK 99117098 T DK99117098 T DK 99117098T DK 99117098 T DK99117098 T DK 99117098T DK 0987256 T3 DK0987256 T3 DK 0987256T3
Authority
DK
Denmark
Prior art keywords
methylisoxazole
trifluoromethylphenyl
carboxylic acid
acid amide
crystal form
Prior art date
Application number
DK99117098T
Other languages
Danish (da)
English (en)
Inventor
Holger Dr Faasch
Udo Dr Hedtmann
Erich Dr Paulus
Uwe Dr Westenfelder
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19734438A external-priority patent/DE19734438A1/de
Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of DK0987256T3 publication Critical patent/DK0987256T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK99117098T 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid DK0987256T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19734438A DE19734438A1 (de) 1997-08-08 1997-08-08 Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE1997156093 DE19756093A1 (de) 1997-12-17 1997-12-17 Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Publications (1)

Publication Number Publication Date
DK0987256T3 true DK0987256T3 (da) 2002-02-11

Family

ID=26038983

Family Applications (2)

Application Number Title Priority Date Filing Date
DK99117098T DK0987256T3 (da) 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
DK98114373T DK0903345T3 (da) 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98114373T DK0903345T3 (da) 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid

Country Status (28)

Country Link
US (5) US6060494A (es)
EP (2) EP0903345B1 (es)
JP (2) JPH11124372A (es)
KR (2) KR100544041B1 (es)
CN (2) CN1181064C (es)
AR (1) AR015418A1 (es)
AT (2) ATE207065T1 (es)
AU (1) AU752764B2 (es)
BR (1) BR9806568A (es)
CA (1) CA2245267C (es)
CZ (3) CZ292943B6 (es)
DE (2) DE59801792D1 (es)
DK (2) DK0987256T3 (es)
ES (2) ES2150808T3 (es)
GR (1) GR3034814T3 (es)
HK (2) HK1017681A1 (es)
HU (2) HU225870B1 (es)
ID (1) ID20667A (es)
IL (1) IL125671A (es)
NO (1) NO310871B1 (es)
NZ (1) NZ331270A (es)
PL (1) PL192126B1 (es)
PT (2) PT987256E (es)
RU (1) RU2224753C2 (es)
SK (2) SK282641B6 (es)
TR (2) TR200600582A1 (es)
TW (1) TW593288B (es)
UA (1) UA54411C2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
DE19908527C2 (de) 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CA2397601A1 (en) 1999-12-16 2001-06-21 Teva Pharmaceutical Industries, Ltd. Novel processes for making- and a new crystalline form of- leflunomide
US6723855B2 (en) * 2000-02-15 2004-04-20 Teva Pharmaceutical Industries Ltd. Method for synthesizing leflunomide
US7022725B2 (en) 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
JPWO2003068239A1 (ja) * 2002-02-12 2005-06-02 住友製薬株式会社 新規外用剤
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
PL1507531T3 (pl) * 2003-03-12 2007-06-29 Teva Pharma Trwałe kompozycje farmaceutyczne desloratadyny
JP4223428B2 (ja) * 2004-03-31 2009-02-12 富士通メディアデバイス株式会社 フィルタおよびその製造方法
WO2007067710A1 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体（上海）有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
UA103189C2 (ru) * 2008-03-10 2013-09-25 Такеда Фармасьютикал Компани Лимитед Кристаллическая форма бензимидазольного соединения
NZ617025A (en) 2009-09-18 2014-03-28 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4’-trifluormethylphenyl)-amide tablet formulations with improved stability
CN103977594B (zh) * 2014-06-03 2016-02-17 江苏九九久科技股份有限公司 一种结晶方法
US9895370B2 (en) * 2015-11-19 2018-02-20 Pharmedix.Co., Ltd Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) * 2018-09-03 2019-01-11 深圳市新阳唯康科技有限公司 一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法
CN114716388B (zh) * 2021-11-04 2024-02-13 江苏冠军科技集团股份有限公司 一种磺胺-银化合物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2525959A1 (de) * 1975-06-11 1977-02-10 Focke Pfuhl Verpack Automat Verpackung fuer zigaretten, zigarillos etc.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
BR9008022A (pt) * 1990-05-18 1993-04-06 Hoechst Ag Amida de acido isoxazol-4-carboxilico e amidas de acido hidroxialquilideno-cianoacetico,medicamentos contendo estes compostos e sua aplicacao
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) * 1992-04-30 1992-06-17 Roussel Lab Ltd Chemical compounds
ES2125356T3 (es) * 1993-01-08 1999-03-01 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 8.
ATE174218T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von interleukin 1 beta
EP0607776B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
TW314467B (es) * 1993-03-31 1997-09-01 Hoechst Ag
GB9320299D0 (en) * 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
ATE194912T1 (de) * 1994-10-17 2000-08-15 Aventis Pharma Ltd Mittel zur vorsorge und heilung von typ i allergischen krankheiten
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
US6096770A (en) * 1998-08-03 2000-08-01 American Home Products Corporation Anthranilic acid analogs
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CA2397601A1 (en) * 1999-12-16 2001-06-21 Teva Pharmaceutical Industries, Ltd. Novel processes for making- and a new crystalline form of- leflunomide
US6723855B2 (en) * 2000-02-15 2004-04-20 Teva Pharmaceutical Industries Ltd. Method for synthesizing leflunomide
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis

Also Published As

Publication number Publication date
CN1089759C (zh) 2002-08-28
HU225870B1 (en) 2007-11-28
HUP9801844A2 (hu) 2000-02-28
CN1208034A (zh) 1999-02-17
CZ246898A3 (cs) 1999-02-17
HK1049481B (zh) 2005-07-08
EP0987256A1 (de) 2000-03-22
DE59800287D1 (de) 2000-11-09
NO983632L (no) 1999-02-09
HU9801844D0 (en) 1998-10-28
TW593288B (en) 2004-06-21
KR20050077498A (ko) 2005-08-02
DK0903345T3 (da) 2000-10-23
EP0903345A1 (de) 1999-03-24
NO983632D0 (no) 1998-08-07
CN1373126A (zh) 2002-10-09
EP0903345B1 (de) 2000-10-04
ES2150808T3 (es) 2000-12-01
UA54411C2 (uk) 2003-03-17
US20030027851A1 (en) 2003-02-06
GR3034814T3 (en) 2001-02-28
US6060494A (en) 2000-05-09
CA2245267A1 (en) 1999-02-08
PT987256E (pt) 2002-03-28
KR19990023433A (ko) 1999-03-25
HUP9801844A3 (en) 2000-04-28
NO310871B1 (no) 2001-09-10
ES2166205T3 (es) 2002-04-01
TR199801513A2 (xx) 1999-02-22
BR9806568A (pt) 2000-05-16
AU752764B2 (en) 2002-09-26
JPH11124372A (ja) 1999-05-11
JP2009280604A (ja) 2009-12-03
RU2224753C2 (ru) 2004-02-27
TR200600582A1 (tr) 2006-08-21
PT903345E (pt) 2001-01-31
HU0700190D0 (en) 2007-05-02
CZ292943B6 (cs) 2004-01-14
ID20667A (id) 1999-02-11
CZ301514B6 (cs) 2010-03-31
US6221891B1 (en) 2001-04-24
PL327901A1 (en) 1999-02-15
SK285216B6 (sk) 2006-09-07
EP0987256B1 (de) 2001-10-17
HK1017681A1 (en) 1999-11-26
TR199801513A3 (tr) 1999-02-22
IL125671A (en) 2002-11-10
KR100544041B1 (ko) 2006-09-18
PL192126B1 (pl) 2006-09-29
ATE207065T1 (de) 2001-11-15
HK1049481A1 (en) 2003-05-16
US20030166945A1 (en) 2003-09-04
DE59801792D1 (de) 2001-11-22
CN1181064C (zh) 2004-12-22
CZ301426B6 (cs) 2010-02-24
CA2245267C (en) 2008-12-23
KR100588254B1 (ko) 2006-06-12
AR015418A1 (es) 2001-05-02
US20040204465A1 (en) 2004-10-14
HU229232B1 (en) 2013-09-30
AU7887098A (en) 1999-02-18
IL125671A0 (en) 1999-04-11
SK282641B6 (sk) 2002-10-08
NZ331270A (en) 2000-04-28
US6552202B2 (en) 2003-04-22
SK105898A3 (en) 1999-02-11
ATE196764T1 (de) 2000-10-15
US6995272B2 (en) 2006-02-07
US6900334B2 (en) 2005-05-31

Similar Documents

Publication Publication Date Title
DK0987256T3 (da) Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
DK1445259T3 (da) Anvendelse af krystalformer for 2-methyl-thieno-benzodiazepin
DE69800430D1 (de) Modulatoren von durch Aminosäuren anregbare Rezeptoren
DE69812007T2 (de) Aliphatische Lösungen von Aminoalkyllithiumverbindungen
CY2012029I2 (el) Nεα μορφη της 5-ομεπραζολης
DE69928195D1 (de) Komplettierung von Untrerdruck-Bohrlöchern
DK0889692T3 (da) Ny anvendelse af N-(phosphonomethyl)glycin og derivater deraf
DK38293D0 (da) Fremstilling af proteiner
ID28779A (id) BENTUK-BENTUK KRISTAL DARI EtO2C-CH2-(R)CgL-Aze-Pab-OH
NL300284I2 (nl) Kristalmodificatie van
CY2005003I2 (el) Mεθοδοι και ενδιαμεσα χρησιμα για κατασκευη αντιφολικων
DK0975217T3 (da) Synergistiske blandinger af udvalgte aminosyrer
DK1102747T3 (da) Krystalformer af osenetant
DK0823876T3 (da) Fremstilling af poser
DE69800559D1 (de) Ferrielektrische Flüssigkristallverbindung
DE69927626D1 (de) Ausführung von Permutationen
DK0980241T3 (da) Gelatineindkapslede opløsningsdosisformer af sertralin
ID23885A (id) Bentuk-bentuk polimorf baru dari cypamfylline
DK0689577T3 (da) Anvendelse af ferroncen
DK1155004T3 (da) Fremgangsmåde til krystallisation af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
DK82592D0 (da) Fremstilling af proteiner
DK0859001T3 (da) Fremstilling af oxazolderivater
DK0840609T3 (da) Anvendelse af usubstituerede og substituerede N-(pyrrol-1-yl)pyridinaminer som antikonvulsive midler
IS5544A (is) Nýtt fosfatsalt af ísóprópýl-metýl-[2-(3-n-própoxýfenoxý)-etýl]amíni
DK1098871T3 (da) Phenylesterderivater af alfa-aminosyrer